In this work, led by Dr. Tim Boyer, we engineered a cationic interleukin-1 receptor antagonist (cat-IL-1Ra) by fusing a cartilage-targeting cationic peptide carrier (CPC) to IL-1Ra. This design enabled selective targeting of anionic cartilage and the formation of intra-articular drug depots. By optimizing the C-terminal CPC fusion, cat-IL-1Ra retained effective receptor binding while achieving prolonged joint residence and preventing IL-1–induced cartilage inflammation. The paper is published online and can be accessed [HERE]!
Congratulations to Dr. Tim Boyer and co-authors on the recent publish work on cartilage targeting IL-1RA to prevent OA inflammation in Osteoarthritis and Cartilage
